Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

Fintel reports that on June 2, 2025, Leerink Partners downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Recent health news includes a promising AstraZeneca pill for breast cancer treatment, Pfizer and Arvinas' experimental drug ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on ...

Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...